GERN
NASDAQ · Biotechnology
Geron Corp
$1.26
+0.03 (+2.44%)
Financial Highlights (FY 2026)
Revenue
193.86M
Net Income
-88,071,351
Gross Margin
97.4%
Profit Margin
-45.4%
Rev Growth
+574.2%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 97.4% | 59.0% | 59.0% | 59.0% |
| Operating Margin | -37.3% | -23.7% | -21.6% | -21.9% |
| Profit Margin | -45.4% | -23.8% | -22.9% | -28.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 193.86M | 153.95M | 141.15M | 142.49M |
| Gross Profit | 188.85M | 90.77M | 83.22M | 84.01M |
| Operating Income | -72,308,055 | -36,512,998 | -30,527,747 | -31,182,512 |
| Net Income | -88,071,351 | -36,660,557 | -32,364,939 | -40,158,948 |
| Gross Margin | 97.4% | 59.0% | 59.0% | 59.0% |
| Operating Margin | -37.3% | -23.7% | -21.6% | -21.9% |
| Profit Margin | -45.4% | -23.8% | -22.9% | -28.2% |
| Rev Growth | +574.2% | +15.1% | +6.9% | +15.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 211.98M | 158.35M | 202.35M | 170.15M |
| Total Equity | 192.18M | 381.18M | 345.34M | 407.50M |
| D/E Ratio | 1.10 | 0.42 | 0.59 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -71,834,733 | -44,322,691 | -40,350,825 | -39,303,619 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 | -39,999,532 |